Nordicus Partners Corporation Corporate Update
MWN-AI** Summary
Nordicus Partners Corporation (OTCQB: NORD), a financial consulting firm focusing on Nordic and U.S. life sciences companies, has provided a significant corporate update on February 6, 2026. The company has detailed advancements in its subsidiaries: Orocidin, Bio-Convert, and NoviThera, alongside the status of its Nasdaq uplisting application.
Orocidin is set to commence its first pilot efficacy study in patients at the University of Copenhagen in Q3 2026. This will follow the completion of GMP (Good Manufacturing Practice) production for clinical use. A pivotal 8-week toxicology study is expected to begin soon, with completion anticipated by April 2026.
Bio-Convert is also making progress, with GMP product finalization scheduled for August 2026. The initiation of patient testing for their product, QR-02, is expected to occur in Q3 2026 in Gothenburg, Sweden.
NoviThera is advancing on schedule, currently conducting a mouse study to assess the impact of different doses of a pathogenic polypeptide on psoriasis development. Results will be reported in about one month, providing clarity on the next steps for their research.
In terms of market positioning, Nordicus is actively pursuing its Nasdaq uplisting application. The process to elevate its shares from the OTCQB Market to the Nasdaq Capital Market is ongoing. Additionally, the company is exploring the Nordic region for new accelerator clients and potential acquisitions within the life sciences industry.
Nordicus is recognized for its unique position as a publicly traded holding company dedicated to Nordic life sciences. The firm has previously acquired 100% stakes in Orocidin A/S and Bio-Convert A/S to strengthen its portfolio in next-generation therapies.
For further inquiries, investors and interested parties can contact CEO Henrik Rouf directly or reach out for media inquiries.
MWN-AI** Analysis
Nordicus Partners Corporation (OTCQB: NORD) presents a compelling investment opportunity in the life sciences sector as it navigates multiple promising developments. With recent advancements in its subsidiaries—Orocidin, Bio-Convert, and NoviThera—the company is strategically positioning itself within the rapidly evolving Nordic and U.S. markets.
Orocidin is on the verge of initiating its first pilot efficacy study, expected to commence in Q3 2026 post-GMP certification. This is a critical milestone, as successful outcomes from the study could significantly enhance the company’s valuation and investor interest. Simultaneously, Bio-Convert is finalizing its GMP product by August 2026, with patient testing set to begin shortly thereafter. This timing aligns well with the market's growing demand for innovative treatments, potentially driving robust revenue streams if clinical results are favorable.
NoviThera's ongoing mouse study will provide valuable insights into psoriasis treatment. Positive results could establish the company as a key player in dermatological therapies, further diversifying its portfolio and attracting strategic partnerships.
Moreover, the intention to uplist to the Nasdaq Capital Market could enhance Nordicus’s visibility and liquidity, attracting institutional investors who prefer listings on larger exchanges. This potential uplisting, alongside the strategic scouting for additional Nordic life science clients and acquisitions, reflects a proactive approach to growth that could reward investors in the long term.
However, investors should approach with caution, as the path to commercialization is fraught with regulatory hurdles and market competition. While the forward-looking statements indicate optimism, these projections are subject to considerable uncertainty. As such, monitoring clinical trial results and uplisting progress will be crucial for potential investors seeking to capitalize on Nordicus's ambitious trajectory in the life sciences arena.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEVERLY HILLS, California, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, is pleased to provide a corporate update, highlighting an overview of developments in its subsidiaries, Oricidin, Bio-Convert and NoviThera, and a status of the Company’s Nasdaq uplisting application.
Orocidin
The first pilot efficacy study in patients is anticipated to start in Q3 2026 at the University of Copenhagen in Denmark.
In order to start the efficacy study, it will begin upon completion of the GMP (Good Manufacturing Practice) for the clinical use of the product. Additionally, a pivotal 8-week toxicology study is about to be initiated and is expected to be completed by April 2026.
Bio-Convert
Bio-Convert expects the final GMP (Good Manufacturing Practice) product to be completed by August 2026.
Patient testing of Bio-Convert’s product, QR-02, is anticipated to begin in Q3 2026 in Gothenburg, Sweden.
NoviThera
NoviThera’s development is progressing according to plan.
A mouse study is currently running in which the mice receive different doses of the pathogenic polypeptide in increasing concentrations comparing control (inactive saline). The objective is to determine whether increasing levels of the polypeptide drives the development of psoriasis.
Once the study is finalized in approximately one month, Nordicus will report the results and the next milestones for NoviThera.
Nasdaq Uplisting
Nordicus applied to uplist its common shares from the OTCQB Market to the Nasdaq Capital Market and the process is still ongoing.
Other Activities
The Company continues to scout the Nordic region for additional accelerator clients and possible new high growth acquisitions in the life sciences space.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn, X, Threads and BlueSky.
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq, studies related to Orocidin, Bio-Convert and NoviThera and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
or
Ulveman G Børsting, media inquiries
kontakt@ulvemanborsting.com
FAQ**
How does Nordicus Partners Corporation's growth strategy differentiate it from competitors like Nord Anglia Education Inc. NORD in the life sciences sector?
What specific milestones does Nordicus foresee achieving that could mirror the success seen by Nord Anglia Education Inc. NORD in terms of market expansion?
Can Nordicus Partners Corporation leverage its expertise to enhance the financial performance of its subsidiaries similar to how Nord Anglia Education Inc. NORD has performed in the education sector?
What lessons can Nordicus Partners Corporation learn from Nord Anglia Education Inc. NORD regarding public market engagement as it seeks Nasdaq uplisting?
**MWN-AI FAQ is based on asking OpenAI questions about Nord Anglia Education Inc. (OTC: NORD).
NASDAQ: NORD
NORD Trading
0.0% G/L:
$4.04 Last:
2,000 Volume:
$4.04 Open:
